Extracranial-intracranial Bypass Surgery for Symptomatic Chronic Middle Cerebral Artery Occlusion: the CMOSS-2 Trial

Infarction, Middle Cerebral Artery Clinical Trial

Official title:

Extracranial-intracranial Bypass Surgery Versus Medical Treatment Alone for Symptomatic Chronic Middle Cerebral Artery Occlusion: the CMOSS-2 Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05899582
• Other study ID #: CMOSS-2
• Status: Recruiting
• Phase: N/A
• Start date: September 15, 2023
• Est. completion date: September 2027

Study information

• Verified date: June 2023
• Source: Xuanwu Hospital, Beijing
• Contact: Yan Ma, MD
• Phone: 13810669502
• Email: leavesyan[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The CMOSS-2 trial is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit symptomatic chronic occlusion of the middle cerebral artery in patients with severe hemodynamic insufficiency. Only high-volume center with a proven track record will be included. Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus bypass surgery. Primary outcome is ischemic stroke in the territory of the target artery within 24 months after randomization.

Description:

Middle cerebral artery occlusion is an important cause of ischemic stroke, and there are currently two treatment methods: medical treatment alone and extracranial-intracranial bypass surgery (EC-IC bypass surgery). Previous studies have shown that the optimal medical treatment has an annual stroke recurrence rate of up to 10%, and patients with concomitant hemodynamic disorders can also increase by 7.3 times.

The CMOSS study was the first trial in China to evaluate the safety and efficacy of EC-IC bypass surgery on patients with ICA or MCA occlusion combined with hemodynamic insufficiency evaluated with CT perfusion. The results showed that there was no significant difference in the risk of stroke or death between the bypass group and the medical group, but there was a significant difference in ipsilateral ischemic stroke between 30 days and 2 years after randomization, with only 2.0% in the surgery group and 10.3% in the medical group; In addition, subgroup analysis found that for patients with MCA occlusion or severe hemodynamic insufficiency, bypass surgery has a potential beneficial trend over medical treatment alone.

The CMOSS-2 trial is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit symptomatic chronic occlusion of the middle cerebral artery in patients with severe hemodynamic insufficiency. Only high-volume center with a proven track record will be included. Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus bypass surgery. Primary outcome is ischemic stroke in the territory of the target artery within 24 months after randomization. The CMOSS-2 trial will be conducted in 13 sites in China.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 420
• Est. completion date: September 2027
• Est. primary completion date: September 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age of 18-65 years;

2. Confirmed as chronic occlusion of unilateral middle cerebral artery (MCA) by angiography. Other cerebral artery stenosis should be less than 50%.

3. CT perfusion demonstrates severe hemodynamic insufficiency in the territory of the qualifying MCA with MTT (symptomatic side) = 6s or rCBF (symptomatic side/contralateral side) = 0.8;

4. mRS score is 0-2 points;

5. A history of ischemic events (including<1/2 cerebral infarction in the middle cerebral artery supply area, or transient ischemic attack [TIA]) related to the qualifying artery within 12 months ;

6. The onset of acute stroke should be more than 1 month;

7. CT or MRI excludes large cerebral infarction (infarction>1/2 of the territory of the qualifying middle cerebral artery);

8. Patients or their guardians voluntarily participate of the study and sign the consent form.

Exclusion Criteria:

1. History of intracranial hemorrhage, subarachnoid hemorrhage, subdural hemorrhage, or extradural hemorrhage within 6 weeks;

2. Unstable angina pectoris or myocardial infarction, congestive heart failure within 6 months;

3. Women who are pregnant or lactating;

4. Coagulation dysfunction or hemorrhagic tendency (e.g. INR > 1.5 and/or platelet count < 100,000 mcL);

5. Other diseases with a life expectancy of less than 2 years

6. Previous treatment with EC-IC bypass surgery

7. Known allergy or contraindication to aspirin or clopidogrel or other antiplatelet drugs.

8. Known cardiac conditions that may lead to cardiogenic embolism: including prosthetic valves, infective endocarditis, left atrial or left ventricular thrombosis, atrial fibrillation, sick sinus node syndrome, atrial mucinous tumor or cardiomyopathy, ejection fraction <25%;

9. Allergy to iodine or x-ray contrast, blood creatinine > 3.0 mg/dl or other contraindications to arteriography

10. Uncontrolled diabetes mellitus with fasting blood sugar (FBS) >16.7 mmol/L

11. Uncontrolled hypertension with a sitting systolic blood pressure >180 mmHg or a sitting diastolic blood pressure >110 mmHg;

12. Persistent worsening of neurological symptoms within 72 hours;

13. Severe liver dysfunction, defined as serum alanine transaminase (ALT) and/or glutamic oxalacetic transaminase (AST) > 3 times the upper limit of normal range;

14. Active peptic ulcer disease;

15. Having received a clinical trial drug or device within 30 days prior to screening, or being enrolled in another clinical trial;

16. Other diseases or medical history that, in the judgment of the investigator, may affect the efficacy or safety evaluation of this study.

Related Conditions & MeSH terms

• Arterial Occlusive Diseases
• Infarction
• Infarction, Middle Cerebral Artery

Intervention

Procedure:
• Extracranial-Intracranial Bypass Surgery
Extracranial-intracranial bypass surgery plus medical treatment

Other:
• Medical treatment alone
Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.

Locations

Country	Name	City	State
China	Xuanwu Hospital, Capital Medical University.	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with ischemic stroke in territory of qualifying artery	Number of participants with ischemic stroke in territory of qualifying artery within 2 years after randomization	2 years after randomization
Secondary	Number of participants with any stroke or death	Number of participants with any stroke or death within 30 days after randomization	30 days after randomization
Secondary	A composite of any stroke or death within 30 days, or ischemic stroke in territory of qualifying artery beyond 30 days to 2 years after randomization	Number of participants with any stroke or death within 30 days, or ischemic stroke in territory of qualifying artery beyond 30 days to 2 years after randomization	within 2 years after randomization
Secondary	Number of participants with any stroke	Number of participants with any stroke within 2 years after randomization	within 2 years after randomization
Secondary	Number of participants with disabling stroke (mRS>3)	Number of participants with disabling stroke within 2 years after randomization	within 2 years after randomization
Secondary	Number of participants with fatal stroke (death caused by a stroke)	Number of participants with fatal stroke within 2 years after randomization	within 2 years after randomization
Secondary	Number of participants with death	Number of participants with death within 2 years after randomization	within 2 years after randomization
Secondary	Number of participants with any stroke or death	Number of participants with any stroke or death within 2 years after randomization	within 2 years after randomization
Secondary	Functional outcomes of participants	Functional outcomes of participants such as modified Rankin scale (mRS) or the National Institutes of Health Stroke Scale (NIHSS) at 2 years after randomization	2 years after randomization
Secondary	Anastomosis patency of participants in surgical group	Anastomosis patency of participants in surgical group at 2 years after randomization	2 years after randomization